Menu
No results found.
📢 Scheduled Break in Updates
Please note that there will be no updates this week as I am taking a well-deserved holiday. Normal updates will resume on Saturday, 30th August. Thank you for your understanding.
Weekly Share Price & Valuation Overview
Actuate Therapeutics, Inc. Common stock
Actuate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancers in the United States. The company's lead product candidate is elraglusib injection, a glycogen synthase kinase-3 inhibitor that is in Phase 2 trial to treat metastatic pancreatic ductal adenocarcinoma. It also develops elraglusib, which is in Phase 1/2 trial for the treatment of refractory pediatric malignancies, including Ewing sarcoma, as well as metastatic melanoma and colorectal cancer. The company was formerly known as Apotheca Therapeutics, Inc. and changed its name to Actuate Therapeutics, Inc. in October 2015. Actuate Therapeutics, Inc. was incorporated in 2015 and is headquartered in Fort Worth, Texas.
- Earnings growth ≥10% supports improving profitability trajectory.
- Net cash balance sheet provides flexibility for downturns and investment.
- Quick ratio <0.8 — tight near-term liquidity without inventory.
- Negative free cash flow — operations may rely on external financing.
- Market Cap Total equity value of the company (share price × shares outstanding).
- USD 163.06M
- Enterprise Value Operating value: market cap + total debt − cash.
- USD 158.85M
- EPS (TTM) Earnings per share over the last twelve months (may be estimated from net income ÷ shares).
- -3.11
- Shares Outstanding
- 20.47M
- Float Shares
- 7.10M
- Implied Shares Outstanding
- 20.47M
- ROA Return on assets: net income ÷ total assets.
-
-3.49%
- Earnings Growth (YoY) Strong Year-over-year earnings growth.
-
30.00%
- Quick Ratio Liquid current assets ÷ current liabilities (ex-inventory).
- 0.71
- Total Cash Cash and equivalents.
- USD 6.49M
- Net Debt Net Cash Total debt − cash (negative = net cash).
- USD -6.49M
- Revenue per Share (TTM) computed from resolved revenue ÷ shares due to feed inconsistency.
Disclaimer: Information is compiled from publicly available sources and is subject to errors and omissions. It is provided as a guide only and does not constitute investment advice. Please do your own research.